WO1992014737A1 - 3-desmethylrapamycin or derivatives thereof, processes for their preparation and their use as antifungal agents and immunosuppressants - Google Patents
3-desmethylrapamycin or derivatives thereof, processes for their preparation and their use as antifungal agents and immunosuppressants Download PDFInfo
- Publication number
- WO1992014737A1 WO1992014737A1 PCT/GB1992/000271 GB9200271W WO9214737A1 WO 1992014737 A1 WO1992014737 A1 WO 1992014737A1 GB 9200271 W GB9200271 W GB 9200271W WO 9214737 A1 WO9214737 A1 WO 9214737A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- desmethylrapamycin
- mixture
- derivative
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92904505A EP0572454B1 (en) | 1991-02-19 | 1992-02-14 | Process for the preparation of 29-desmethylrapamycin and its use as antifungal or immunosuppressant agent |
JP50418792A JP3245158B2 (en) | 1991-02-19 | 1992-02-14 | 3-desmethylrapamycin or a derivative thereof, their preparation, and their use as antifungals and immunosuppressants |
DE69231898T DE69231898T2 (en) | 1991-02-19 | 1992-02-14 | METHOD FOR PRODUCING 29-DESMETHYLRAPAMYCIN AND ITS USE AS A FUNGICIDE OR IMMUNOSUPPRESSIVA |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9103430.6 | 1991-02-19 | ||
GB919103430A GB9103430D0 (en) | 1991-02-19 | 1991-02-19 | Novel compound |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/311,290 Continuation US6358969B1 (en) | 1991-02-19 | 1994-09-23 | 3-desmethylrapamycin or derivatives thereof, processes for their preparation and their use as antifungal agents and immunosuppressants |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992014737A1 true WO1992014737A1 (en) | 1992-09-03 |
Family
ID=10690214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1992/000271 WO1992014737A1 (en) | 1991-02-19 | 1992-02-14 | 3-desmethylrapamycin or derivatives thereof, processes for their preparation and their use as antifungal agents and immunosuppressants |
Country Status (6)
Country | Link |
---|---|
US (1) | US6358969B1 (en) |
EP (1) | EP0572454B1 (en) |
JP (2) | JP3245158B2 (en) |
DE (1) | DE69231898T2 (en) |
GB (1) | GB9103430D0 (en) |
WO (1) | WO1992014737A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016189A1 (en) * | 1992-02-17 | 1993-08-19 | Pfizer Inc. | Novel macrocyclic lactones and a productive strain thereof |
EP0562853A1 (en) * | 1992-03-27 | 1993-09-29 | American Home Products Corporation | 29-Demethoxyrapamycin for inducing immunosuppression |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
US5318895A (en) * | 1992-10-05 | 1994-06-07 | Merck & Co., Inc. | Aspergillus niger mutants |
WO1994018208A1 (en) * | 1993-02-10 | 1994-08-18 | Smithkline Beecham Plc | 7,42-bis (o-demethyl) rapamycin |
EP0648494A1 (en) * | 1993-09-30 | 1995-04-19 | American Home Products Corporation | Rapamycin formulations for oral administration |
EP0650729A1 (en) * | 1993-09-30 | 1995-05-03 | American Home Products Corporation | Rapamycin formulations for IV injection |
US5728710A (en) * | 1992-07-17 | 1998-03-17 | Smithkline Beecham Corporation | Rapamycin derivatives |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
CN1107500C (en) * | 1993-09-30 | 2003-05-07 | 惠氏公司 | Rapamycin formulations for oral administration |
CN1108152C (en) * | 1993-09-30 | 2003-05-14 | 惠氏公司 | Rapamycin formulations for oral administration |
US6565859B1 (en) | 1993-05-27 | 2003-05-20 | Novartis Ag | Galenical formulations |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US7196192B2 (en) | 1999-08-24 | 2007-03-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
WO2008144567A1 (en) * | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Method of purification of rapamycin and its analogs by use of cascade chromatography |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
CN103343101A (en) * | 2013-06-21 | 2013-10-09 | 赤峰创诺医药科技有限公司 | Inclined surface culture medium for terramycin strains |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
EP3663405A1 (en) | 2013-06-11 | 2020-06-10 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
WO2001090021A1 (en) * | 2000-05-25 | 2001-11-29 | Sumitomo Osaka Cement Co., Ltd. | Thermoplastic hydraulic composition, formed product prepared from the composition by hardening through hydration thereof, and method for preparing the formed product |
UA82328C2 (en) | 2002-07-30 | 2008-04-10 | Уайт | Parenteral formulations of rapamycin hydroxyester (variants) and a method for its preparation |
CN1946852A (en) * | 2004-04-27 | 2007-04-11 | 惠氏公司 | Labeling of rapamycin using rapamycin-specific methylases |
AU2006331874A1 (en) * | 2005-12-20 | 2007-07-05 | Wyeth | Control of CCI-779 dosage form stability through control of drug substance impurities |
US20080051691A1 (en) * | 2006-08-28 | 2008-02-28 | Wyeth | Implantable shunt or catheter enabling gradual delivery of therapeutic agents |
US20100196355A1 (en) * | 2007-01-29 | 2010-08-05 | Wyeth | Immunophilin Ligands and Methods for Modulating Immunophilin and Calcium Channel Activity |
WO2009105510A1 (en) * | 2008-02-19 | 2009-08-27 | Wyeth | Methods for using rapamycin analogues in the treatment of neurological disorders |
CN113620978A (en) | 2014-09-11 | 2021-11-09 | 加利福尼亚大学董事会 | mTORC1 inhibitors |
US20190336609A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors |
AU2019262979B2 (en) | 2018-05-01 | 2023-07-06 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
CN113164563A (en) | 2018-07-23 | 2021-07-23 | 因柯利尔疗法公司 | Method of treatment of neurological disorders |
EP3826650A4 (en) | 2018-07-23 | 2022-07-27 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
EP3952947A1 (en) | 2019-04-11 | 2022-02-16 | Enclear Therapies, Inc. | Methods of amelioration of cerebrospinal fluid and devices and systems therefor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3993749A (en) * | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US5093338A (en) * | 1991-04-23 | 1992-03-03 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
US5091389A (en) * | 1991-04-23 | 1992-02-25 | Merck & Co., Inc. | Lipophilic macrolide useful as an immunosuppressant |
JP3140228B2 (en) | 1992-02-17 | 2001-03-05 | ファイザー製薬株式会社 | Novel macrocyclic lactone and its producing bacteria |
-
1991
- 1991-02-19 GB GB919103430A patent/GB9103430D0/en active Pending
-
1992
- 1992-02-14 DE DE69231898T patent/DE69231898T2/en not_active Expired - Fee Related
- 1992-02-14 EP EP92904505A patent/EP0572454B1/en not_active Expired - Lifetime
- 1992-02-14 JP JP50418792A patent/JP3245158B2/en not_active Expired - Fee Related
- 1992-02-14 WO PCT/GB1992/000271 patent/WO1992014737A1/en active IP Right Grant
-
1994
- 1994-09-23 US US08/311,290 patent/US6358969B1/en not_active Expired - Fee Related
-
2001
- 2001-01-04 JP JP2001000167A patent/JP2001226380A/en active Pending
Non-Patent Citations (1)
Title |
---|
Canadian Journal of Chemistry, vol. 60, no. 15, 1982, (Ottawa, CA), J.A. FINDLAY et al.: "The structure of demethoxyrapamycin", pages 2046-2047, see abstract; compounds 1,2 * |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993016189A1 (en) * | 1992-02-17 | 1993-08-19 | Pfizer Inc. | Novel macrocyclic lactones and a productive strain thereof |
EP0562853A1 (en) * | 1992-03-27 | 1993-09-29 | American Home Products Corporation | 29-Demethoxyrapamycin for inducing immunosuppression |
US5728710A (en) * | 1992-07-17 | 1998-03-17 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5318895A (en) * | 1992-10-05 | 1994-06-07 | Merck & Co., Inc. | Aspergillus niger mutants |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5597715A (en) * | 1993-02-10 | 1997-01-28 | Smithkline Beecham P.L.C. | 7,42-Bis(O-demethyl)rapamycin |
WO1994018208A1 (en) * | 1993-02-10 | 1994-08-18 | Smithkline Beecham Plc | 7,42-bis (o-demethyl) rapamycin |
US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
US7025975B2 (en) | 1993-05-27 | 2006-04-11 | Novartis Ag | Galenical formulations |
US6565859B1 (en) | 1993-05-27 | 2003-05-20 | Novartis Ag | Galenical formulations |
EP0648494A1 (en) * | 1993-09-30 | 1995-04-19 | American Home Products Corporation | Rapamycin formulations for oral administration |
CN1108152C (en) * | 1993-09-30 | 2003-05-14 | 惠氏公司 | Rapamycin formulations for oral administration |
CN1107500C (en) * | 1993-09-30 | 2003-05-07 | 惠氏公司 | Rapamycin formulations for oral administration |
US5616588A (en) * | 1993-09-30 | 1997-04-01 | American Home Products Corporation | Rapamycin formulation for IV injection |
EP0650729A1 (en) * | 1993-09-30 | 1995-05-03 | American Home Products Corporation | Rapamycin formulations for IV injection |
AU688782B2 (en) * | 1993-09-30 | 1998-03-19 | Wyeth | Rapamycin formulations for oral administration |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
US6649595B2 (en) | 1995-06-07 | 2003-11-18 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using novel compounds |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US7196192B2 (en) | 1999-08-24 | 2007-03-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
EP2181704A2 (en) | 2002-12-30 | 2010-05-05 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
WO2008144567A1 (en) * | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Method of purification of rapamycin and its analogs by use of cascade chromatography |
US8921642B2 (en) | 2008-01-11 | 2014-12-30 | Massachusetts Eye And Ear Infirmary | Conditional-stop dimerizable caspase transgenic animals |
EP3663405A1 (en) | 2013-06-11 | 2020-06-10 | Takara Bio USA, Inc. | Protein enriched microvesicles and methods of making and using the same |
CN103343101A (en) * | 2013-06-21 | 2013-10-09 | 赤峰创诺医药科技有限公司 | Inclined surface culture medium for terramycin strains |
CN103343101B (en) * | 2013-06-21 | 2015-03-25 | 赤峰创诺医药科技有限公司 | Inclined surface culture medium for terramycin strains |
Also Published As
Publication number | Publication date |
---|---|
US6358969B1 (en) | 2002-03-19 |
DE69231898D1 (en) | 2001-08-02 |
GB9103430D0 (en) | 1991-04-03 |
EP0572454B1 (en) | 2001-06-27 |
JP3245158B2 (en) | 2002-01-07 |
EP0572454A1 (en) | 1993-12-08 |
DE69231898T2 (en) | 2002-04-04 |
JPH06505150A (en) | 1994-06-16 |
JP2001226380A (en) | 2001-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0572454B1 (en) | Process for the preparation of 29-desmethylrapamycin and its use as antifungal or immunosuppressant agent | |
US5491229A (en) | Rapamycin derivative | |
EP0349061B1 (en) | Immunosuppressant agent | |
DK169550B1 (en) | Tricyclo compounds, process for their preparation, use thereof, preparations containing them, and Streptomyces tsukubaensis microorganism culture for use in the process | |
US4981792A (en) | Immunosuppressant compound | |
US4375464A (en) | Antibiotic AY24,668 and process of preparation | |
US5712129A (en) | Rapamycin derivative with antimicrobial, anticancer and immunomodulation activity | |
EP0388153B1 (en) | Immunosuppressant agent | |
US4987139A (en) | FK-520 microbial transformation product | |
EP0683784B1 (en) | 7,42-bis (o-demethyl) rapamycin | |
EP0358508A3 (en) | Novel immunosuppressant compound | |
US5583018A (en) | Rapamycin derivative process for its preparation and its use | |
US5359060A (en) | Phosponated derivatives of macrolides | |
EP0403242A1 (en) | New L-683,590 microbial transformation product | |
US5252612A (en) | Microbial immunosoppressant agent | |
EP0396400A1 (en) | Microbial transformation product | |
US5270187A (en) | Microbial transformation product | |
EP0378320A2 (en) | Microbial transformation product | |
CA2071332A1 (en) | C-21 hydroxylated fk-506 antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1992904505 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1993 107736 Date of ref document: 19931019 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1992904505 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWG | Wipo information: grant in national office |
Ref document number: 1992904505 Country of ref document: EP |